SOX17 and mucinous adenocarcinoma: Accordingly, we speculate that SOX17 may contribute to immune evasion in early non‐mucinous adenocarcinoma in situ; however, extensive experimental proof is needed to verify this hypothesis by examining SOX17 expression in the precancerous lesion, such as atypical bronchioloalveolar cell hyperplasia of the lung.